Movers and SHAKERS
Lineage Cell Therapeutics (LCTX)
Additional Data Presented Confirms Our OpRegen Expectations
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 1/2a development for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.OpRegen Data Presented At ARVO. Lineage Cell Therapeutics presented data from the Phase 1/2a trial testing OpRegen, its retinal pigment epithelial cell transplantation for treating age-related macular degeneration (dry AMD). The data was presented at the Annual Meeting of the Association for Research in Vison and Ophthalmology, ARVO. The presentation added additional patient data from its last cohort, demonstrating safety, tolerability, and improvements in visual function and cellular structure.
Additional Data From The Efficacy Cohort Was Presented. The Phase 1/2a trial is an open-label trial with three cohorts of 4 patients each receiving ascending doses to establish safety, then a fourth cohort of 12 patients to test efficacy. Patients in the updated presentation have been assessed at 12 months following OpRegen treatment, with some patients followed for up to 5 years....
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.